PuSH - Publication Server of Helmholtz Zentrum München

Ziegler, C.G.* ; Ullrich, M.* ; Schally, A.V.* ; Bergmann, R.* ; Pietzsch, J.* ; Gebauer, L.* ; Gondek, K.* ; Qin, N.* ; Pacak, K.* ; Ehrhart-Bornstein, M.* ; Eisenhofer, G.* ; Bornstein, S.R.*

Anti-tumor effects of peptide analogs targeting neuropeptide hormone receptors on mouse pheochromocytoma cells.

Mol. Cell. Endocrinol. 371, 189-194 (2013)
DOI Order publishers version
Open Access Green as soon as Postprint is submitted to ZB.
Pheochromocytoma is a rare but potentially lethal chromaffin cell tumor with currently no effective treatment. Peptide hormone receptors are frequently overexpressed on endocrine tumor cells and can be specifically targeted by various anti-tumor peptide analogs. The present study carried out on mouse pheochromocytoma cells (MPCs) and a more aggressive mouse tumor tissue-derived (MTT) cell line revealed that these cells are characterized by pronounced expression of the somatostatin receptor 2 (sst2), growth hormone-releasing hormone (GHRH) receptor and the luteinizing hormone-releasing hormone (LHRH) receptor. We further demonstrated significant anti-tumor effects mediated by cytotoxic somatostatin analogs, AN-162 and AN-238, by LHRH antagonist, Cetrorelix, by the cytotoxic LHRH analog, AN-152, and by recently developed GHRH antagonist, MIA-602, on MPC and for AN-152 and MIA-602 on MTT cells. Studies of novel anti-tumor compounds on these mouse cell lines serve as an important basis for mouse models of metastatic pheochromocytoma, which we are currently establishing.
Altmetric
Additional Metrics?
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
ISSN (print) / ISBN 0303-7207
e-ISSN 1872-8057
Quellenangaben Volume: 371, Issue: 1-2, Pages: 189-194 Article Number: , Supplement: ,
Publisher Elsevier
Publishing Place Shannon
Reviewing status Peer reviewed
Institute(s) Institute for Pancreatic Beta Cell Research (IPI)